1. Home
  2. NWN vs VRDN Comparison

NWN vs VRDN Comparison

Compare NWN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northwest Natural Holding Company

NWN

Northwest Natural Holding Company

HOLD

Current Price

$50.36

Market Cap

2.1B

Sector

Utilities

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$23.02

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWN
VRDN
Founded
1859
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2018
2014

Fundamental Metrics

Financial Performance
Metric
NWN
VRDN
Price
$50.36
$23.02
Analyst Decision
Buy
Strong Buy
Analyst Count
3
14
Target Price
$54.33
$35.46
AVG Volume (30 Days)
180.1K
1.9M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
3.71%
N/A
EPS Growth
36.45
N/A
EPS
2.33
N/A
Revenue
$1,289,363,000.00
$5,706,000.00
Revenue This Year
$11.37
$13.73
Revenue Next Year
$4.46
$279.00
P/E Ratio
$21.83
N/A
Revenue Growth
11.83
N/A
52 Week Low
$40.09
$13.18
52 Week High
$55.99
$34.29

Technical Indicators

Market Signals
Indicator
NWN
VRDN
Relative Strength Index (RSI) 51.24 68.75
Support Level $48.33 $17.97
Resistance Level $51.20 $33.71
Average True Range (ATR) 0.91 1.03
MACD 0.05 0.13
Stochastic Oscillator 54.65 88.31

Price Performance

Historical Comparison
NWN
VRDN

About NWN Northwest Natural Holding Company

Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in three reportable business segments, which are NWN Gas Utility, SiEnergy, and NWN Water. The company generates maximum revenue from NWN Gas Utility segment. It also generates revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: